Interleukin 6 and lipopolysaccharide binding protein - Markers of inflammation in acute appendicitis

Chirurgia (Romania)

Volumn 108, Issue 2, 2013, Pages 206-214

  Branescu C ^a   Serban D ^a   Dascalu A M ^a   Oprescu, S M ^a   Savlovschi C ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Acute appendicits; Acute inflammation; Acute phase proteins; Correlations; Interleukin 6; Lipopolysaccharide binding protein (LPS BP, LBP); Pathology; Sepsis

Indexed keywords

EID: 84878337790     PISSN: 12219118     EISSN: 1842368X     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Zweigner J, Schumann RR, Weber Jr. The role of lipopolysaccharide- binding protein in modulating the innate immune response. Microbes Infect. 2006;8(3): 946-52. Epub 2006 Jan 13.
2. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, et al. Structure and function of lipopolysaccharide binding protein. Science. 1990;249(4975): 1429-31.
3. Su GL, Freeswick PD, Geller DA, Wang Q, Shapiro RA, Wan YH, et al. Molecular cloning, characterization, and tissue distribution of rat lipopolysaccharide binding protein. Evidence for extrahepatic expression. J Immunol. 1994;153(2): 743-52.
4. Dentener MA, Vreugdenhil AC, Hoet PH, Vernooy JH, Nieman FH, Heumann D, et al. Production of the acute-phase protein lipopolysaccharide-binding protein by respiratory type II epithelial cells: implications for local defense to bacterial endotoxins. Am J Respir Cell Mol Biol. 2000;23(2): 146-53.
5. Weber JR, Freyer D, Alexander C, Schroder NW, Reiss A, Kuster C, et al. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity. 2003;19(2): 269-79.
6. Gray PW, Corcorran AE, Eddy RL Jr, Byers MG, Shows TB. The genes for the lipopolysaccharide binding protein (LBP) and the bactericidal permeability increasing protein (BPI) are encoded in the same region of human chromosome 20. Genomics. 1993;15(1): 188-90.
7. Desrumaux C, Labeur C, Verhee A, Tavernier J, Vandekerckhove J, Rosseneu M, Peelman F. A hydrophobic cluster at the surface of the human plasma phospholipid transfer protein is critical for activity on high density lipoproteins. J Biol Chem. 2001;276(8): 5908-15. Epub 2000 Nov 16.
8. Rietschel ET, Brade H, Holst O, Brade L, Muller-Loennies S, Mamat U, et al. Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol. 1996;216: 39-81.
9. Hamann L, Alexander C, Stamme C, Zahringer U, Schumann RR. Acute-phase concentrations of lipopolysaccharide (LPS)- binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms. Infect Immun. 2005;73(1): 193-200.
10. Bingle CD, Craven CJ. PLUNC: a novel family of candidate host defence proteins expressed in the upper airways and nasopharynx. Hum Mol Genet. 2002;11(8): 937-43.
11. Tobias PS, Mathison J, Mintz D, Lee JD, Kravchenko V, Kato K, et al. Participation of lipopolysaccharide-binding protein in lipopolysaccharide- dependent macrophage activation. Am J Respir Cell Mol Biol. 1992;7(3): 239-45.
12. Kirschning C, Unbehaun A, Lamping N, Pfeil D, Herrmann F, Schumann RR. Control of transcriptional activation of the lipopolysaccharide binding protein (LBP) gene by proinflammatory cytokines. Cytokines Cell Mol Ther. 1997;3(1): 59-62.
13. Lamping N, Dettmer R, Schroder NW, Pfeil D, Hallatschek W, Burger R, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest. 1998;101(10): 2065-71.
14. Tobias PS, Soldau K, Ulevitch RJ. Ulevitch. 1986. Isolation of a lipopolysaccharide- binding acute phase reactant from rabbit serum. J Exp Med. 1986;164(3): 777-93.
15. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem. 1989;264(18): 10867-71.
16. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38: 417-32.
17. Rietschel ET, Brade H, Brade L, Brandenburg K, Schade U, Seydel U, et al. Lipid A, the endotoxic center of bacterial lipopolysaccharides: relation of chemical structure to biological activity. Prog Clin Biol Res. 1987;231: 25-53.
18. Schumann RR, Rietschel ET, Loppnow H. The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin. Med Microbiol Immunol. 1994;183(6): 279-97.
19. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115(6): 457-69.
20. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet. 1991;338(8769): 732-6.
21. Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol. 1999;11(1): 19-22.
22. Blunck R, Scheel O, Muller M, Brandenburg K, Seitzer U, Seydel U. New insights into endotoxin-induced activation of macrophages: involvement of a K channel in transmembrane signaling. J Immunol. 2001;166(2): 1009-15.
23. Maruyama N, Kakuta Y, Yamauchi K, Ohkawara Y, Aizawa T, Ohrui T, et al. Quinine inhibits production of tumor necrosis factor- from human alveolar macrophages. Am J Respir Cell Mol Biol. 1994;10(5): 514-20.
24. Dentener MA, Von Asmuth EJ, Francot GJ, Marra MN, Buurman WA. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide- induced cytokine release by mononuclear phagocytes: competition for binding to lipopolysaccharide. J Immunol. 1993;151(8): 4258-65.
25. Heumann D, Gallay P, Barras C, Zaech P, Ulevitch RJ, Tobias PS, et al. Control of lipopolysaccharide (LPS) binding and LPSinduced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol. 1992;148(11): 3505-12.
26. Gallay P, Heumann D, Le Roy D, Barras C, Glauser MP. Lipopolysaccharide- binding protein as a major plasma protein responsible for endotoxemic shock. Proc Natl Acad Sci U S A. 1993;90(21): 9935-8.
27. Wurfel MM, Monks BG, Ingalls RR, Dedrick RL, Delude R, Zhou D, et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med. 1997;186(12): 2051-6.
28. Jack RS, Fan X, Bernheiden M, Rune G, Ehlers M, Weber A, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature. 1997;389(6652): 742-5.
29. Gutsmann T, Haberer N, Carroll SF, Seydel U, Wiese A. Interaction between lipopolysaccharide (LPS), LPS-binding protein (LBP), and planar membranes. Biol Chem. 2001; 382(3): 425-34.
30. Yu B, Hailman E, Wright SD. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest. 1997;99(2): 315-24.
31. Gallay P, Heumann D, Le Roy D, Barras C, Glauser MP. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci U S A. 1994;91(17): 7922-6.
32. Le Roy D, Di Padova F, Tees R, Lengacher S, Landmann R, Glauser MP, et al. Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. J Immunol. 1999;162(12): 7454-60.
33. Wurfel MM, Monks BG, Ingalls RR, Dedrick RL, Delude R, Zhou D, et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med. 1997;186(12): 2051-6.
34. Jack RS, Fan X, Bernheiden M, Rune G, Ehlers M, Weber A, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature. 1997; 389(6652): 742-5.
35. Fierer J, Swancutt MA, Heumann D, Golenbock D. The role of lipopolysaccharide binding protein in resistance to Salmonella infections in mice. J Immunol. 2002;168(12): 6396-403.
36. Knapp S, de Vos AF, Florquin S, Golenbock DT, van der Poll T. Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice. Infect Immun. 2003;71(12): 6747-53.
37. Fan MH, Klein RD, Steinstraesser L, Merry AC, Nemzek JA, Remick DG, et al. An essential role for lipopolysaccharidebinding protein in pulmonary innate immune responses. Shock. 2002;18(3): 248-54.
38. Jawa RS, Anillo S, Huntoon K, Baumann H, Kulaylat M. Analytic review: Interleukin-6 in surgery, trauma, and critical care: part I: basic science. J Intensive Care Med. 2011;26(1): 3-12. doi: 10.1177/0885066610395678.
39. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334 (Pt 2): 297-314.
40. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: antiinflammatory and immunosuppressive mediators. Immunol Today. 1997;18(9): 428-32.
41. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acutephase responses in interleukin-6-deficient mice. Nature. 1994;368(6469): 339-42.
42. Kushner I, Rzewnicki DL. The acute phase response: general aspects. Baillieres Clin Rheumatol. 1994;8(3): 513-30.
43. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3): 621-36.
44. Kushner I. C-reactive protein in rheumatology. Arthritis Rheum. 1991;34(8): 1065-8.
45. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004;279(47): 48487-90. Epub 2004 Aug 26.
46. Arredouani MS, Kasran A, Vanoirbeek JA, Berger FG, Baumann H, Ceuppens JL. Haptoglobin dampens endotoxininduced inflammatory effects both. in vitro. and in vivo. Immunology. 2005;114(2): 263-71.
47. Mortensen RF, Zhong W. Regulation of phagocytic leukocyte activities by C-reactive protein. J Leukoc Biol. 2000;67(4): 495-500.
48. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(3):S233-S242.
49. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(1):S4-S10.
50. Cronstein BN. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(1):S11-S15.
51. Biffl WL, Moore EE, Moore FA, Carl VS, Kim FJ, Franciose RJ. Interleukin-6 potentiates neutrophil priming with plateletactivating factor. Arch Surg. 1994;129(11): 1131-1136.
52. Nijsten MW, Hack CE, Helle M, ten Duis HJ, Klasen HJ, Aarden LA. Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery. 1991;109(6): 761-767.
53. Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006;195(4): 173-183.
54. Peng J, Friese P, George JN, Dale GL, Burstein SA. Alteration of platelet function in dogs mediated by interleukin-6. Blood. 1994; 83(2): 398-403.
55. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica. 2000;85(9): 967-972.
56. Ahad A. Baumann H, Elias J, et al. Interleukin-6-type cytokines in diagnostics and therapeutics: roundtable discussion. Ann N Y Acad Sci. 1995;762: 375-387.
57. Dimopoulou I, Tsagarakis S, Kouyialis AT, Roussou P, Assithianakis G, Christoforaki M, et al. Hypothalamic-pituitaryadrenal axis dysfunction in critically ill patients with traumatic brain injury: incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 levels. Crit Care Med. 2004;32(2): 404-8.
58. Kashiwabara M, Miyashita M, Nomura T, Makino H, Matsutani T, Kim C, et al. Surgical traumainduced adrenal insufficiency is associated with postoperative inflammatory responses. J Nippon Med Sch. 2007;74(4): 274-83.
59. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128(2): 127-137.
60. Chesnokova V, Melmed S. Minireview: neuro-immunoendocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology. 2002;143(5): 1571-4.
61. Wasmuth HE, Kunz D, Graf J, Stanzel S, Purucker EA, Koch A, et al. Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-alpha. Crit Care Med. 2004;32(5): 1109-14.
62. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6- dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278(16): 13740-6. Epub 2003 Jan 30.
63. Beeton CA, Chatfield D, Brooks RA, Rushton N. Circulating levels of interleukin-6 and its soluble receptor in patients with head injury and fracture. J Bone Joint Surg Br. 2004;86(6): 912-917.
64. Dekkers PE, Juffermans NP, ten Hove T, de Jonge E, van Deventer SJ, van der Poll T. Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans. J Infect Dis. 2000;181(3): 1055-1061.
65. Yahara N, Abe T, Morita K, Tangoku A, Oka M. Comparison of interleukin-6, interleukin-8, and granulocyte colony-stimulating factor production by the peritoneum in laparoscopic and open surgery. Surg Endosc. 2002;16(11): 1615-1619.
66. Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monden M, et al. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery. 1992;111(2): 201-9.
67. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992; 215(4): 356-62.
68. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74(5): 1704-10.